Wattana Karnpaet Valuation
Is NEW-R undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEW-R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NEW-R (THB90) is trading above our estimate of fair value (THB72.33)
Significantly Below Fair Value: NEW-R is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEW-R?
Other financial metrics that can be useful for relative valuation.
What is NEW-R's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ฿900.00m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.7x |
Enterprise Value/EBITDA | 7.6x |
PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does NEW-R's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 29.1x | ||
IMH Intermedical Care and Lab Hospital | 67.2x | 77.5% | ฿1.4b |
KDH Thonburi Medical Centre | 16.7x | n/a | ฿1.8b |
AHC Aikchol Hospital | 14.5x | n/a | ฿2.7b |
RPH Ratchaphruek Hospital | 18.1x | n/a | ฿3.3b |
NEW-R Wattana Karnpaet | 16x | n/a | ฿900.0m |
Price-To-Earnings vs Peers: NEW-R is good value based on its Price-To-Earnings Ratio (16x) compared to the peer average (29.1x).
Price to Earnings Ratio vs Industry
How does NEW-R's PE Ratio compare vs other companies in the TH Healthcare Industry?
Price-To-Earnings vs Industry: NEW-R is good value based on its Price-To-Earnings Ratio (16x) compared to the TH Healthcare industry average (26.8x).
Price to Earnings Ratio vs Fair Ratio
What is NEW-R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 16x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NEW-R's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.